PharmaCyte is developing cellular therapies for cancer and diabetes based on a proprietary live-cell encapsulation technology known as “Cell-in-a-Box®.” This chemotherapy allows targeting of the treatment near the tumor, resulting in fewer of the typical chemo side effects. It has been effective and safe in clinical trials and will be used for several types of cancer and diabetes therapies being developed.
Some of the therapies PharmaCyte is developing for cancer are derived from cannabinoids and will also use the Cell in a Box technology. It is not clear whether the current clinical trials will involve cannabis-derived therapies.
Selection of Medpace was led by Dr. Linda Sher, PharmaCyte’s Chief Medical Officer, and Dr. Manuel Hidalgo, who will serve as Principal Investigator for the trial.